(Q53769196)

English

Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22150087

Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention. (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22150087

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Bjørn Tore Gjertsen

6

object named as

Bjørn T Gjertsen

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

author name string

Håkon Reikvam

1

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22150087

Kimberley J Hatfield

2

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22150087

Elisabeth Ersvaer

3

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22150087

Randi Hovland

4

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22150087

Jørn Skavland

5

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22150087

Kjell Petersen

7

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22150087

Oystein Bruserud

8

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22150087

language of work or name

0 references

publication date

13 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22150087

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22150087

156

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22150087

4

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22150087

468-480

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22150087

Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

Acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

The Crosstalk Between the Matrix Metalloprotease System and the Chemokine Network in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

Analysis of gene-expression data using J-Express

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08960.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2011.08960.X

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22150087

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 May 2018

http://europepmc.org/abstract/MED/22150087

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53769196&oldid=1235591278"